Coriolis Pharma Invests in Growth by Creating a New Campus in Martinsried-Munich

Coriolis Pharma is expanding its current headquarters with additional facilities to form a new Campus.

MARTINSRIED-MUNICH, Germany, June 03, 2022 / B3C newswire / – Coriolis Pharma, a global operating contract research and development organization (CRDO) and one of the world leaders in formulation research and development of (bio) pharmaceutical drugs, ATMP´s and vaccines, is expanding its current headquarters to a new Campus as the next step in its growth strategy.

Pic1

Caption: Plans for the new Coriolis Campus in the Fraunhoferstrasse in Martinsried-Munich

For high resolution please click the image.

Located in the heart of the Biotech Hotspot Martinsried, the new Coriolis Campus will double the overall capacities to 14.000 sqm. It will include two new buildings (Fraunhoferstrasse 14 and F14b), the current headquarters (F18b), and two additional locations (F8 and F11a). The new Campus with interconnected buildings will provide the company with sustainable growth opportunities. The first building will be operational in early 2024, while the completion of the entire Coriolis Campus is planned for 2025.

“Coriolis Pharma is investing heavily in creating new attractive jobs in Martinsried,” said Silvia Steyrer-Gruber, CEO of Coriolis Pharma. “The Coriolis Campus will be designed for our employees, offering new workspaces, meeting zones, a conference center and an employee restaurant. We formulate innovation by the way of working together, we formulate innovation and revolutionize formulation development. ”

The possibility to purchase an additional site in the proximity to Coriolis’ headquarter in Martinsried is exciting for Coriolis. In the highly competitive real estate market in Martinsried, Coriolis has a large and globally competitive space, as it provides a highly specialized contract research and development organization (CRDO).

“We will plan and develop all facilities to be energy-efficient and sustainable,” said Dr. Michael Wiggenhorn, Member of the Board of Directors. “We will focus on energy by photovoltaics and geothermal sources as part of our concepts. Green spaces, planting of the roofs and facades will complete the Coriolis Campus feeling for our employees. It is important to contribute to our environment, besides focusing on our aim to enable the development of innovative therapies to improve the quality of life of humankind. ”

In the first construction phase, and modern lab infrastructure, including multipurpose facilities and office spaces will be established. In a second construction phase, a new facility with an employee’s restaurant and places to meet, it will allow for innovative and smooth processes within a stimulating working environment. This new facility will connect people and generate the heart of the Coriolis Campus.

About Coriolis Pharma
Coriolis Pharma is a global operating service provider and one of the world’s leaders in formulation research and development of (bio) pharmaceutical drugs and vaccines.
The motivation of the team is to enable the development of innovative drugs by performing excellent biopharmaceutical research to improve the quality of life for humankind.
The vision of Coriolis Pharma is to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. Coriolis Pharma enables humankind efficiently and on time.
Coriolis Pharma provides cutting-edge services and tailor-made solutions for their clients.
Coriolis company culture is based on diversity, teamwork, and open and appreciative communication. That’s why wonderful people from over 25 nations around the world work together successfully at Coriolis.

Contact

Coriolis Pharma Research GmbH
Dr. Daniel Weinbuch
Scientific Marketing Specialist
+49 (0) 89 4177 60 – 149
This email address is being protected from spambots. You need JavaScript enabled to view it.
Fraunhoferstr. 18b
82152 Martinsried-Munich
Germany

Keywords: Facility Design and Construction; Laboratories; Drug Compounding; Research; Drug Delivery Systems; Biological Products; Drug Therapy; Pharmaceutical Preparations; Germany

Published by B3C newswire

.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker